Merck & Co., Inc. Business Acquisition, Cost of Acquired Entity, Purchase Price (Deprecated 2013-01-31)
Merck & Co., Inc. (MRK) had Business Acquisition, Cost of Acquired Entity, Purchase Price (Deprecated 2013-01-31) of $420.00 million as of 2011-05-30, per its 10-Q filed 2012-08-07.
Discontinued › Notes › Business Combinations
us-gaap:BusinessAcquisitionCostOfAcquiredEntityPurchasePrice · last filed 2012-11-09
- 2011-05-30: Business Acquisition, Cost of Acquired Entity, Purchase Price (Deprecated 2013-01-31) $420.00M.
- 2011-05-16: Business Acquisition, Cost of Acquired Entity, Purchase Price (Deprecated 2013-01-31) $420.00M.
- 2010-02-01: Business Acquisition, Cost of Acquired Entity, Purchase Price (Deprecated 2013-01-31) $190.00M.
| Period end | Business Acquisition, Cost of Acquired Entity, Purchase Price (Deprecated 2013-01-31) |
|---|---|
| 2011-05-30 | $420.00M 10-Q · filed 2012-08-07 |
| 2011-05-16 | $420.00M 10-Q · filed 2012-11-09 |
| 2010-02-01 | $190.00M 10-Q · filed 2010-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |